Acutus Medical, Inc.
Acutus Medical, Inc. (AFIB) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
afib · stock forecast · 6 analysts (3M) · FMP · updated May 30, 2026
Analyst Rating & Consensus
Based on 6 Wall Street analysts in the past 3 months
Hold
6 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$1.50
Consensus
$1.50
+749900.0% upside
Low
$1.50
Median: $1.5 · Last Close: $0.00
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $0.00 | ↑ 0.00% |
1-day model range: $0–$0. Peak: $0 (+0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · AFIB · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2022-08-16 | Goldman Sachs | Maintains | Neutral→Neutral |
| 2022-06-24 | BTIG | Maintains | Buy→Buy |
| 2022-04-27 | BTIG | Upgrade ↑ | Neutral→Buy |
| 2022-04-14 | Goldman Sachs | Maintains | Neutral→Neutral |
| 2022-01-20 | BTIG | Downgrade ↓ | Buy→Neutral |
| 2022-01-14 | Canaccord Genuity | Downgrade ↓ | Buy→Hold |
| 2021-11-12 | Canaccord Genuity | Maintains | Buy→Buy |
| 2021-11-12 | JP Morgan | Downgrade ↓ | Neutral→Underweight |
| 2021-07-15 | Canaccord Genuity | Upgrade ↑ | Hold→Buy |
| 2021-03-19 | William Blair | Downgrade ↓ | Outperform→Market Perform |
Wall Street analysts have recently issued updated ratings on Acutus Medical, Inc. (AFIB) stock. Of the recent 13 rating actions, 2 were upgrades and 6 were downgrades. 6 analysts currently cover AFIB.
Analyst Recommendation Trends
AFIB analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$21M
↓ 63.3% YoY
Revenue Next Year
$30M
↑ 46.1% YoY
EPS This Year
$-2.39
EPS Next Year
$-1.56
↓ 34.6% YoY
EPS ForecastReported vs Estimated
Analysts forecast AFIB EPS of $-2.39 for the current fiscal year, based on estimates from 2 analysts. The AFIB revenue forecast is $21M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The AFIB stock forecast is supported by two independent data sources: analyst consensus ratings from 6 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus AFIB price target is $1.50 (+749900.0% upside), with an analyst consensus of Hold.
The AFIB short-term stock prediction for tomorrow is $0.00 (+0.00%).
Acutus Medical, Inc. trades on OTC under the ticker AFIB. The AFIB stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 17% of covering analysts.
Frequently asked questions
AFIB forecast · 8 questionsAccording to 6 Wall Street analysts, the average 12-month AFIB price target is $1.50, with a high forecast of $1.50 and a low of $1.50. The median price target is shown in the chart above when available. This implies +749900.0% potential upside from the current price of $0.00.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.